NSCLC harbors several driver mutations in oncogenes like RAS, EGFR, BRAF, ALK, ROS1 and MET that frequently lead to the hyperactivation of MAPKs [55, 56]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.